02 Jul2021

SQZ Biotechnologies Strengthens Board with Global Commercial and Clinical Development Experience

Written by 2020HCP.com. Posted in News

Bernard Coulie, M.D., Ph.D. and Patrick Vink, M.D. Join Board of Directors

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the appointments of Bernard Coulie, M.D., Ph.D., and Patrick Vink, M.D., to its board of directors, adding global commercial and clinical development expertise.

23 Jun2021

SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor

Written by 2020HCP.com. Posted in News

Results Further Establish Company’s Broad Cell Engineering Capabilities and Potential to Direct Cell Fate for Multiple Therapeutic Applications

Findings Presented at 2021 International Society for Stem Cell Research Annual Meeting

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented preclinical regenerative medicine data showing that the company’s Cell Squeeze® technology can be used to generate neurons from induced human pluripotent stem cells (iPSCs) through the single delivery of an mRNA encoding fate-specifying transcription factor.

09 Jun2021

SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases

Written by 2020HCP.com. Posted in News

Engineered TACs Prevented Hyperglycemia in Type 1 Diabetes Models by Deletion of Target T Cells and Increase of Regulatory T Cells that Exerted Potent Bystander Suppression

Data Presented at Federation of Clinical Immunology Societies

08 Jun2021

Zixi Announces Global Rollout Of ZaaS

Written by 2020HCP.com. Posted in News

Zixi as a Service provides a complete solution for end-to-end IP video delivery without the need to manage infrastructure. 

Today Zixi announced the global availability of Zixi as a Service (ZaaS), broadcast infrastructure as a service that enables media companies and service providers to quickly ingest and distribute live video over any IP with ultra-low latency.

04 Jun2021

SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors

Written by 2020HCP.com. Posted in News

Doses of Autologous Cell Therapy Manufactured in Under 24 Hours and Available to Patients in Approximately One Week

Clinical Trial Findings Presented at the American Society of Clinical Oncology Annual Meeting

WATERTOWN, Mass.–(BUSINESS WIRE)– SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV demonstrating that the investigational cell therapy is safe and well-tolerated and can stimulate immune responses in certain patients with advanced or metastatic Human Papillomavirus positive (HPV16+) tumors. The trial also showed that the company’s clinical stage manufacturing process of its autologous cell therapy is fast and reliable. The monotherapy stage trial data of the company’s first Antigen Presenting Cell (APC) platform candidate was presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting; poster presentation 2536.

Latest News